阿法替尼治疗：使用口服药物治疗非小细胞肺癌时不良事件的实际管理
Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.
作者信息
Edwards Rebecca L, Andan Christine, Lalla Rajesh V, Lacouture Mario E, O'Brien Dennis, Sequist Lecia V
机构信息
University of Alabama.
Boehringer Ingelheim Pharmaceuticals.
出版信息
Clin J Oncol Nurs. 2018 Oct 1;22(5):542-548. doi: 10.1188/18.CJON.542-548.
Abstract
BACKGROUND
Afatinib is an oral, irreversible ErbB family blocker indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with non-resistant epidermal growth factor receptor (EGFR) mutations. Afatinib is also approved for the treatment of metastatic squamous NSCLC following progression on platinum-based chemotherapy. Common afatinib-associated toxicities include gastrointestinal and dermatologic events, which can be dose limiting.
OBJECTIVES
In this review, the authors describe clinical trial experiences with afatinib, as well as best practices and practical approaches to the management of afatinib-associated adverse events in EGFR mutation-positive NSCLC.
METHODS
Safety and tolerability data from phase 3 trials of afatinib were reviewed, together with real-life experiences from the authors' clinical practices.
FINDINGS
Patient education, combined with early assessment and effective management of afatinib-related adverse events as well as dose- reduction strategies, allows patients to continue treatment and maximize the clinical benefits of afatinib.
摘要
背景
阿法替尼是一种口服的、不可逆的表皮生长因子受体（ErbB）家族阻滞剂，适用于一线治疗具有非耐药性表皮生长因子受体（EGFR）突变的转移性非小细胞肺癌（NSCLC）患者。阿法替尼也被批准用于治疗铂类化疗进展后的转移性鳞状NSCLC。阿法替尼常见的相关毒性包括胃肠道和皮肤事件，这些可能会限制剂量。
目的
在本综述中，作者描述了阿法替尼的临床试验经验，以及在EGFR突变阳性NSCLC中管理阿法替尼相关不良事件的最佳实践和实用方法。
方法
回顾了阿法替尼3期试验的安全性和耐受性数据，以及作者临床实践中的实际经验。
结果
患者教育，结合对阿法替尼相关不良事件的早期评估和有效管理以及剂量减少策略，使患者能够继续治疗并最大化阿法替尼的临床益处。
相似文献
1
Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.阿法替尼治疗：使用口服药物治疗非小细胞肺癌时不良事件的实际管理
Clin J Oncol Nurs. 2018 Oct 1;22(5):542-548. doi: 10.1188/18.CJON.542-548.
2
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
3
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).阿法替尼剂量调整对 EGFR 突变阳性晚期 NSCLC 患者安全性和有效性的影响：一项全球真实世界研究（RealGiDo）的结果。
Lung Cancer. 2019 Jan;127:103-111. doi: 10.1016/j.lungcan.2018.10.028. Epub 2018 Nov 2.
4
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.阿法替尼对比吉非替尼用于治疗表皮生长因子受体突变阳性的非小细胞肺癌患者的一线治疗（LUX-Lung 7）：一项 2B 期、开放标签、随机对照临床试验。
Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12.
5
A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).一项 afatinib 低起始剂量作为 EGFR 突变阳性非小细胞肺癌（KTORG1402）一线治疗的 II 期研究。
Lung Cancer. 2019 Sep;135:175-180. doi: 10.1016/j.lungcan.2019.03.030. Epub 2019 Mar 28.
6
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.观察性研究：阿法替尼序贯奥希替尼治疗 EGFR 突变阳性 NSCLC：起始剂量为 40mg 的阿法替尼治疗患者。
Adv Ther. 2020 Feb;37(2):759-769. doi: 10.1007/s12325-019-01187-y. Epub 2019 Dec 20.
7
A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.一项在初治的伴有 EGFR 突变的晚期非小细胞肺癌患者中使用阿法替尼和贝伐珠单抗的 I 期临床试验：冈山中肺癌研究组试验 1404。
Lung Cancer. 2018 Jan;115:103-108. doi: 10.1016/j.lungcan.2017.11.025. Epub 2017 Nov 28.
8
Afatinib for the treatment of mutation-positive NSCLC: A review of clinical findings.阿法替尼用于治疗突变阳性非小细胞肺癌：临床研究结果综述
J Oncol Pharm Pract. 2020 Sep;26(6):1461-1474. doi: 10.1177/1078155220931926. Epub 2020 Jun 20.
9
Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.真实世界中日方 1600 多例 EGFR 突变阳性非小细胞肺癌患者每日使用阿法替尼治疗的情况。
Int J Clin Oncol. 2019 Aug;24(8):917-926. doi: 10.1007/s10147-019-01439-5. Epub 2019 Apr 5.
10
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.一线阿法替尼治疗后 EGFR 突变阳性非小细胞肺癌患者的后续治疗方案测序。
Lung Cancer. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.
引用本文的文献
1
Outcome measures reported by cancer patients treated with tyrosine kinase inhibitors: a methodological study.接受酪氨酸激酶抑制剂治疗的癌症患者报告的结局指标：一项方法学研究。
Rev Bras Enferm. 2025 Mar 31;78(2):e20240018. doi: 10.1590/0034-7167-2024-0018. eCollection 2025.
2
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database.用于非小细胞肺癌的酪氨酸激酶抑制剂的安全性概况：来自意大利药物警戒数据库的分析。
Front Oncol. 2022 Nov 23;12:1005626. doi: 10.3389/fonc.2022.1005626. eCollection 2022.
3
Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.特泊替尼：治疗 MET 外显子 14 跳跃型非小细胞肺癌患者的不良反应。
Clin J Oncol Nurs. 2022 Sep 15;26(5):543-551. doi: 10.1188/22.CJON.543-551.
4
SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.SH-1028，一种不可逆的第三代表皮生长因子受体酪氨酸激酶抑制剂，可克服非小细胞肺癌中T790M介导的耐药性。
Front Pharmacol. 2021 Apr 27;12:665253. doi: 10.3389/fphar.2021.665253. eCollection 2021.
5
Afatinib for the treatment of mutation-positive NSCLC: A review of clinical findings.阿法替尼用于治疗突变阳性非小细胞肺癌：临床研究结果综述
J Oncol Pharm Pract. 2020 Sep;26(6):1461-1474. doi: 10.1177/1078155220931926. Epub 2020 Jun 20.
6
Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy.载阿法替尼的可吸入 PLGA 纳米粒用于非小细胞肺癌（NSCLC）的局部治疗：开发与体外疗效。
Drug Deliv Transl Res. 2021 Jun;11(3):927-943. doi: 10.1007/s13346-020-00802-8.
7
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.一线达可替尼治疗日本晚期非小细胞肺癌患者的安全性和疗效。
Cancer Sci. 2020 May;111(5):1724-1738. doi: 10.1111/cas.14384. Epub 2020 Apr 14.
本文引用的文献
1
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.地塞米松漱口液（SWISH）预防激素受体阳性、HER2 阴性转移性乳腺癌女性患者接受依维莫司相关口腔炎：一项单臂、2 期试验。
Lancet Oncol. 2017 May;18(5):654-662. doi: 10.1016/S1470-2045(17)30109-2. Epub 2017 Mar 15.
2
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.剂量调整对阿法替尼治疗表皮生长因子受体突变阳性肺腺癌的安全性和疗效的影响：随机 LUX-Lung 3 和 6 试验的事后分析。
Ann Oncol. 2016 Nov;27(11):2103-2110. doi: 10.1093/annonc/mdw322. Epub 2016 Sep 6.
3
Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights.表皮生长因子受体抑制剂诱发的痤疮样皮疹：文献综述与新见解
Skin Appendage Disord. 2015 Mar;1(1):31-7. doi: 10.1159/000371821. Epub 2015 Feb 13.
4
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.阿法替尼对比吉非替尼用于治疗表皮生长因子受体突变阳性的非小细胞肺癌患者的一线治疗（LUX-Lung 7）：一项 2B 期、开放标签、随机对照临床试验。
Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12.
5
Impact of dermatologic adverse events induced by targeted therapies on quality of life.靶向治疗引起的皮肤不良反应对生活质量的影响。
Crit Rev Oncol Hematol. 2016 May;101:158-68. doi: 10.1016/j.critrevonc.2016.03.003. Epub 2016 Mar 5.
6
Clinical Appearance of Oral Candida Infection and Therapeutic Strategies.口腔念珠菌感染的临床表现及治疗策略
Front Microbiol. 2015 Dec 17;6:1391. doi: 10.3389/fmicb.2015.01391. eCollection 2015.
7
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.泛加皮疹试验：一项评价预防皮肤治疗方案对转移性肺癌患者表皮生长因子受体酪氨酸激酶抑制剂相关皮肤毒性影响的随机 III 期试验。
J Clin Oncol. 2016 Mar 10;34(8):810-5. doi: 10.1200/JCO.2015.62.3918. Epub 2015 Nov 16.
8
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.英国表皮生长因子受体酪氨酸激酶抑制剂不良事件管理专家共识
Drugs. 2015 Aug;75(12):1335-48. doi: 10.1007/s40265-015-0434-6.
9
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.阿法替尼对比厄洛替尼二线治疗晚期肺鳞癌患者（LUX-Lung 8）：一项开放标签、随机对照、III 期临床研究。
Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.
10
Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.随机、开放标签试验评估四环素对非小细胞肺癌患者阿法替尼诱导皮肤毒性的预防作用。
Lung Cancer. 2015 Jun;88(3):282-8. doi: 10.1016/j.lungcan.2015.03.019. Epub 2015 Mar 28.
Zotero 插件